Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with Evolocumab.
Journal: NEJM evidence
Published: December 24, 2024
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
Journal: The New England journal of medicine
Published: November 13, 2020
Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure: The COSMIC-HF Trial.
Journal: Circulation. Heart failure
Published: November 12, 2020
The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF).
Journal: European journal of heart failure
Published: October 12, 2020
Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
Journal: The New England journal of medicine
Published: September 01, 2020
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials.
Journal: European journal of heart failure
Published: August 29, 2020
Real-World Analysis of Guideline-Based Therapy After Hospitalization for Heart Failure.
Journal: Journal of the American Heart Association
Published: August 18, 2020
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial.
Journal: JAMA cardiology
Published: May 21, 2020
Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial.
Journal: JAMA cardiology
Published: April 30, 2020
Cognition After Lowering LDL-Cholesterol With Evolocumab.
Journal: Journal of the American College of Cardiology
Published: December 02, 2019
Last Updated: 09/26/2026